Sartorius | SRT3 - Gross Profit On Sales

Stock Price
219.60
Daily Change
3.50 1.62%
Monthly
-8.16%
Yearly
-4.56%
Q2 Forecast
199.57

Sartorius reported EUR414.5M in Gross Profit on Sales for its fiscal quarter ending in March of 2026.





Gross Profit On Sales Change Date
Akebia Therapeutics USD 47.28M 1.7M Dec/2025
Alaunos Therapeutics USD -1.13M 1.11M Sep/2024
Avita Medical AUD 14.31M 639K Dec/2025
Dianthus Therapeutics USD 284K 112K Dec/2025
Ionis Pharmaceuticals USD 243M 48M Mar/2026
IQVIA Holdings USD 1.07B 52M Mar/2026
Moderna USD -566M 792M Mar/2026
Organon & Co USD 854M 3M Dec/2025
Revvity USD 387.66M 34M Mar/2026
Sartorius EUR 414.5M 18.3M Mar/2026
Tectonic Therapeutic USD 0 0 Mar/2025
Viatris USD 1.38B 229.9M Mar/2026
Xeris Pharmaceuticals USD 72.15M 8.77M Dec/2025